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Abstract  
Background: The complement pathway has potential contributions to both white (WM) and grey matter 
(GM) pathology in Multiple Sclerosis (MS). A quantitative assessment of complement involvement is 
lacking. 
Objective: Tissue MicroArray methodology was used in conjunction with immunohistochemistry to 
investigate the localization of complement pathway proteins in progressive MS cortical GM and 
subcortical WM.  
Methods: Antibodies targeting complement proteins C1q, C3b, regulatory proteins C1 inhibitor (C1INH), 
complement receptor 1 (CR1), clusterin, factor H (FH) and the C5a anaphylatoxin receptor (C5aR) were 
utilised alongside standard markers of tissue pathology. All stained slides were digitised for quantitative 
analysis.  
Results: Numbers of cells immunolabelled for HLA-DR, GFAP, C5aR, C1q and C3b were increased in 
WM lesions (WML) and GM lesions (GML) compared to normal appearing WM (NAWM) and GM 
(NAGM), respectively. The complement regulators C1INH, CR1, FH and clusterin were more abundant 
in WM lesions, while the number of C1q+ neurons were increased and the number of C1INH+, 
clusterin+, FH+ and CR1+ neurons decreased in GM lesions. The number of complement component 
positive cells (C1q, C3b) correlated with complement regulator expression in WM, but there was no 
statistical association between complement activation and regulator expression in the GM. 
Conclusion: Tissue microarray methodology and quantitative analysis provides evidence of complement 
dysregulation in MS GML, including an association of the numerical density of C1q+ cells with tissue 
lesions. Our work confirms that complement activation and dysregulation occur in all cases of progressive 
MS and suggest that complement may provide potential biomarkers of the disease. 
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Introduction 
Pathology in multiple sclerosis (MS) is typified by white matter lesions (WML), with characteristic 
inflammation, demyelination and axonal loss (neuro-degeneration)12,18,19,25. Lesions are also found in sub-
cortical and cortical grey matter (GML), the latter being a hallmark of the progressive 
phase2,4,7,14,17,22,27,29,30. 
There is an urgent need to uncover the components of the CNS inflammatory response responsible for 
white and grey matter pathology in progressive MS in order to inform therapies that slow pathological 
and neurological decline. Among the implicated components, there is growing pathological evidence for a 
significant contribution of complement (C), to neuro-inflammation in MS3,5,14,16,21,23,37. 
Activation of C is a major driver of inflammation and pivotal to innate and adaptive immune responses24. 
Glia and neurons synthesize the classical pathway activation protein C1q, which binds numerous potential 
ligands to initiate activation and generation of active products, including the lytic membrane attack 
complex (MAC) and the anaphylactic/chemotactic peptides C3a and C5a, chemo-attractants for microglia 
expressing C5aR8,38. To limit self-injury, neurons and glia express numerous C regulatory proteins 
(CReg) including C1INH (C1 activation blockade), CR1, FH (alternative pathway regulation) and 
clusterin (MAC assembly inhibition)38.  
We have previously reported detailed quantitative immunohistochemical studies of complement proteins, 
activators and regulators, showing increased C in plaque, peri-plaque and NAWM of progressive MS 
compared to normal non-inflammatory control tissue16 as well as in cortical grey matter lesions compared 
to non-inflamed control tissue37. Other studies in MS have focussed on determining cellular localization 
of individual C proteins 1,5,21. Here, to better understand the role of C activation and regulation in 
progressive MS we have used tissue microarray (TMA) methodology36, quantitative pathology and 
statistical analysis. This approach provides an unbiased, high throughput methodology for analysing 
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tissue for localization of key C proteins and regulators that can be correlated with measures of pathology 
in white and grey matter MS lesions. 
 
Material and Methods  
Post-mortem cohort 
Archived formalin fixed paraffin embedded (FFPE) tissue blocks obtained at autopsy from clinically and 
neuropathologically validated progressive MS cases were provided by the Multiple Sclerosis Tissue Bank 
Imperial College, London, under South East Wales Research Ethics committee approval [10/WSE02/4]). 
Tissue blocks were sampled from neocortex (WM and GM) and subcortical (WM and GM) sites.  
Fourteen blocks from 13 cases of progressive MS were used: mean age 51.1 years (38-79); clinical 
diagnosis: 9 secondary progressive MS (SPMS) (2 different FFPE blocks were used for case MS230): 4 
primary progressive MS (PPMS). Clinical information, including age, sex, clinical onset and disease 
course are presented in Table 1a. 
FFPE tissue blocks were obtained from cases of Alzheimer’s disease (n=4; frontal and temporal lobe) and 
Herpes Simplex virus encephalitis (n=2; temporal lobe; supplied by Brains for Dementia Research, 
Institute of Psychiatry Kings College, London, UK and The Thomas Willis Brain Bank, Oxford 
University, Oxford, UK) as positive staining controls for this study. All blocks were stained with the 
same antibodies, in the same experimental run, as the TMA cores (Table 1b, supplementary figures 1-3). 
FFPE tissue blocks were also obtained from control non-inflammatory brain tissue cortex of three cases; 
CO38, CO40, CO41 (see table 1b for clinical details and tissue preservation times), as described in the 
control cohort of Ingram and Loveless 201416. Tissue blocks were provided by the Multiple Sclerosis 
Tissue Bank Imperial College, London. 
 
Lesion Classification  
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From each FFPE block, 4 micron sections were cut and stained with haematoxylin & eosin (H&E) and 
Luxol fast blue (LFB). Immunohistochemistry for lesion classification was performed following 
deparaffinisation and rehydration through a graded series of ethanol:H2O mixtures. Antigen retrieval was 
performed using 0.05% citraconic anhydride (pH 7.4; Sigma) and all immunohistochemistry (IHC) was 
performed using a DAKO autostainer, as previously described16.  
Lesion classification was based on staining with the following antibody panel: anti-HLA-DR, anti-Iba 
(ionized calcium binding adaptor molecule 1, microglia marker), anti-MOG (myelin oligodendrocyte 
glycoprotein), anti-CD20 (B lymphocyte marker) and anti-CD3 (pan-T lymphocyte marker) (see Table 2).  
 
Identification of demyelinated white matter and grey matter lesions for TMA construction 
Conventional histological staining with H&E, LFB, anti-HLA and anti-MOG identified areas containing 
WML or GML. Applying criteria described by Lassmann18,19, all WML selected were classified as slowly 
expanding-chronic active plaques (residual inflammation in centre of demyelinated plaque with peripheral 
boundary of activated microglia/ macrophages containing myelin degradation products). Cortical GML 
were classified as type I (involving cortical GM and subcortical WM), type II (intracortical) or type III 
(involving the subpial layers of the neocortex) cortical GML based on location, according to Peterson26. 
WML and GML immunolabelling for B and T cell lymphocytes was restricted to a perivascular and 
meningeal distribution in all sections16.  
A single block per case, except for two blocks from two independent lesions (case MS230), containing 
either chronic active WML or type 1 cortical GML or both, of sufficient size for tissue core sampling, 
were selected following neuropathological analysis for tissue microarray construction. 
 
Tissue selection and construction of TMA 
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In all MS cases, three separate tissue cores (0.6mm diameter; 0.28mm2 area) were obtained from each 
lesion or normal tissue area. Extraction of three tissue cores per area of interest has been shown to 
increase concordance between quantification obtained with TMA cores and conventional wax sections36. 
A Beecher MTA-1 manual tissue arrayer (Estigen OU, Tartu, Estonia), with a needle punch of diameter 
0.6mm, was inserted into the marked areas on the donor blocks corresponding to the site of the lesion. 
The donor tissue core was inserted into the recipient paraffin wax block according to the array 
coordinates defined in the pre-determined template. Two TMA wax blocks were assembled; one 
containing 120 tissue cores, the other, 110 cores taken from the 14 individual FFPE donor blocks, as 
described. In total, 224 tissue cores were available for analysis (6 were not usable) with WM (n=51), 
WML (n=82; including WM lesion centre and WM lesion edge), GM (n=56), GML (n=35; including GM 
lesion centre and GM lesion edge) (see Figure 1). 
 
Immunohistochemistry 
From each TMA block, 4 micron thick sections were cut. The following antibodies were used to detect C 
activation proteins and CReg; mAb C3-30 (detects opsonins C3b and iC3b), anti-C1q, anti-C1INH, anti-
CR1, anti-clusterin, anti-C5aR. A panel of three anti-FH antibodies and a mAb (MBC-125) recognising 
FH-related proteins 1, 2 and 5 (FHR 1,2,5) were included to differentiate staining for FH and the FHRs. 
Sections from the TMAs, control inflammatory brain tissue and control non-inflammatory brain tissue, as 
detailed above, were processed and stained as described (see Table 2 for antibody details and staining 
conditions, and supplementary figures 1, 2 & 3). Appropriate isotype-staining with anti-IgG1 antibody 
using control and negative control tissue were also included with each using methods described16.37. Anti-
fibrinogen antibody was used to stain paraffin wax sections of kidney, TMA and control non-inflamed 
cortex cases (see supplementary figure 1). 
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In situ hybridisation 
In situ hybridisation (ISH) was performed using a 5’ fluorescein (FAM)-labelled 19mer antisense 
oligonucleotide containing nucleic acid (LNA) and 2’-O-methyl (2’-O-Me)-RNA moieties in a 1:2 ratio. 
Probes: antisense C1QA (NM_015991) FAM-TggTccTugAugTuuCcu; scrambled C1QA FAM-
GuuGuuCggTcuCuaGucT; antisense C3 (NM_000064) FAM-TaaTccAccAauCauTucT; sense C3 FAM-
AgaAauGauUggUggAuuA (capitals indicate LNA and lower case 2’-O-Me RNA; Eurogentec, 
Southampton, UK). Following de-waxing, rehydration and antigen retrieval, sections were pre-hybridised 
in hybridisation mix37 before probe hybridisation for 30mins in the same solution. Sections were then 
washed in decreasing concentrations of saline-sodium citrate buffer, washed in PBS, incubated with a 
peroxidase conjugated goat anti-FAM (Vector Labs) and visualised with DAB. Sections were then 
blocked, incubated with mouse anti-Human HuC/HuD neuronal protein overnight (clone 16A11, 
ThermoFisher Scientific), followed by a horse anti-mouse biotin conjugated secondary, an avidin-biotin-
AP tertiary and Vector Blue AP substrate (all Vector Labs), Sections were dehydrated, cleared in 
histoclear and coverslipped in VectaMount (Vector Labs). 
 
Quantification of TMA immunolabelling  
Individual immunolabelled TMA cores were digitally imaged (Zeiss Mirax slide scanner and Pannoramic 
Viewer 3DHistech software). Quantification was performed manually using Image J software 
(http://rsb.info.nih.gov/ij/) by observers (JWN, PS, OWH) blinded to TMA identity and antibody 
labelling; data were exported to Excel (Microsoft Office 2010). Total number of neurons was quantified 
from the LFB stained slides, identified by the presence of an apical dendrite, nucleus and nucleolus. For 
analysis, each core was classified, the cells counted and considered individually. The median number of 
immunolabelled cells per tissue core (0.28mm2) for each C protein or cell phenotype marker was 
calculated and statistical analysis carried out using R v3 0.2 software (https://www.R-project.org/).  
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Statistical analysis  
Comparisons in NAWM vs. WML and NAGM vs. GML of the total number of immunolabelled cells for 
each antibody-stained core was performed using Mann-Whitney U tests and significance taken if p<0.05. 
For each tissue of interest, numbers of immunolabelled cells were counted for individual tissue cores; 
three separate cores were obtained from each lesion or normal tissue sample. 
In order to examine the relationship between individual pairs of anti-C antibodies, the number of cells 
staining positively for each antibody was used as a continuous variable. Pearson correlation was used to 
examine the relationship between pairs of anti-C antibodies. All statistical analysis was performed using 
R v3 0.2 software (https://www.R-project.org/). 
 
 
Results  
Anti-fibrinogen staining kidney and brain tissues 
Kidney sections stained with anti-fibrinogen antibody (see table 2 for details) demonstrated positive 
immunostaining. In brain, cortical anti-fibrinogen antibody staining was localised to blood vessel walls 
but was absent in nearby neurons and surrounding neuropil, indicating a lack of blood-brain barrier 
disruption (supplementary figure 1); this interpretation was in accord with the findings of van Horssen et 
al35. Similar results were obtained using anti-IgG on control brain tissues showing no evidence for 
staining of neurons or glia in accord with published results16 and supporting the lack of anti-fibrinogen 
staining interpretation as demonstrating an intact blood brain barrier. 
 
Control non-inflamed brain tissue 
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Formalin fixed sections from three cases of non-inflamed cortex (C038, CO40, CO41, table 1b) were 
stained with the same anti-C antibodies as used for the TMA sections (supplementary figure 1). In all 
cases there was minimal positive immunostaining of neurons and glia replicating our previous results for 
non-inflamed cortex16. There were significantly lower numbers of immunostained neurons and glia in 
control non-inflamed tissue as compared to NAWM and NAGM in MS tissue16. The non-inflamed tissues 
in this study were from the same cohort as the previous study.  
Neurons and glia from cases of other neuroinflammatory diseases were often positively stained with anti-
C antibodies; examples of typical staining patterns are shown in the supplemental data (supplementary 
figures 2 and 3). 
 
Astrocytic and microglia activation correlate with elevated numbers of C5aR-positive cells 
We compared cores taken from NAGM, GML, NAWM, and WML (figures 1 & 2) areas in TMA 
preparations to better understand the role of complement activation in demyelinating lesions. Astrocytes 
(GFAP+) were found in higher numbers in WML (p<0.0001) in comparison to NAWM (figure 2A). 
There was a significant increase of GFAP+ cells in GML, (p<0.0001), compared to NAGM. GFAP+ 
astrocytes represented only ~10% of total glia in lesion tissue. There was no difference in the number of 
Iba-1 immunolabelled microglia in either WML or GML compared to NAWM or NAGM, respectively; 
however, HLA-DR+ activated microglia were increased in WML (p<0.0001), as compared to NAWM, 
and in GML compared to NAGM (p<0.0001). In all tissue types, microglia represented the most frequent 
immunolabelled cell type (figure 2A). 
Anti-C5aR antibody positively immunostained microglia and a small number of cells with an astrocytic 
morphology; neurons were negative for C5aR as previously reported22. C5aR positive cells were 
increased in WML in comparison to matched NAWM (p<0.003, figure 2B).  
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Immunolabelling for C component proteins and regulators in lesion versus non-lesion tissue 
Total number of C1q immunolabelled cells was increased in WML and GML tissue compared to NAWM 
(p<3 x 10-8) and NAGM (p<0.007), respectively (figure 3A). Total number of C3b immunopositive cells 
per core was also increased in WML and GML tissue compared to NAWM (p<0.0009) and NAGM 
(p<0.03) respectively (figure 3B).  
We performed ISH for C1QA and C3 mRNA to test whether cortical neurons are a source of complement 
in the MS brain (figure 3). Transcripts of C1QA and C3 were detected in the soma of numerous cortical 
neurons that were immunostained for the pan-neuronal protein HuC/D. Sections incubated in the absence 
of probe (not shown), or with scrambled or sense probe, were negative (figure 3). 
C1INH-positive glia were increased in WML compared to NAWM (p=2.7x10-5; figure 4A). CR1-positive 
immunolabelled cells were increased in WML tissue compared to NAWM (p<0.001) (figure 4B). FH-
immunolabelled glial cells were increased in WML in comparison to NAWM, detected using polyclonal 
(p<0.005) and monoclonal antibodies against distinct FH regions (Ox-24 versus FH N-terminus; MBI-15 
versus SCRs 11-15; both p<0.01) (figure 4C,E,F). MBI-15 stains only FH (not FHL or FHRs); staining 
with polyclonal anti-FH and MBI-15 were highly correlated in all TMA cores (R2=0.69) and for neuronal 
staining (R2=0.83; data not shown). Immunolabelling with MBC-125, specific for FH-related (FHR) 
proteins 1, 2 and 5 (present as hetero-oligomers in vivo), demonstrated increased immunopositive glia in 
WML compared to NAWM (p<0.002) (figure 4G). The number of clusterin-positive cells was also 
significantly increased in WML cores (figure 4D) 
In contrast to findings in WM, we did not observe any difference between the number of GML and 
NAGM C1INH, CR1, FH (using polyclonal FH and mAbs Ox-24 and MBI-15) or FHR (MBC-125 
antibody) immuno-positive cells (figure 5); however, clusterin-positive cells were increased in GML 
cores in comparison to NAGM (p<0.05, figure 5D). 
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Complement immunolabelling of neurons  
We investigated whether neurons and non-neuronal cells (glial; microglia and astrocytes) stained for C 
components and regulators, and whether the specific C staining differed between NAGM and GML. 
Positively stained neurons and non-neuronal cells were identified and quantified for each of our panel of 
antibodies (tables 3a,b). Overall, total number of neurons did not differ between NAGM and GML cores 
(data not shown).  C1q-positive and C3b-positive non-neuronal cells were increased in GML compared to 
NAGM (p<0.0001 and p<0.0002, respectively) with an accompanying increase in the number of cells 
positive for regulators and inhibitors (CR1, FH, FHR and clusterin [all p<0.05, table 3a]). However, in 
contrast, significantly fewer neurons in GML were immuno-stained for C regulators C1INH, CR1, FH 
(Ox-24) and FHR proteins compared to neurons in NAGM (all p<0.05); the number of neurons 
expressing clusterin was similar in GML and NAGM. These data suggest a degree of C dysregulation in 
GML neurons. In support of this, there was a marked increase in the number of C1q-positive neurons in 
GML compared to NAGM (p=0.0003), but no difference in C3b-positive neurons (table 3b).  
 
Testing the relationship between individual C component staining in MS WM and GM 
Correlation of C protein staining (on microglia, astrocytes, neurons) was tested for  (i) all cores (table 4a), 
(ii) white matter cores only (NAWM, WML; edge and centre) (table 4b) and (iii) grey matter cores only 
(NAGM, GML; edge and centre) (table 4c). Across all cores, some C components were highly correlated 
with relevant regulators, while others were not. Total C1q immunopositive cells positively correlated with 
C3b immuno-stained cells (Pearson’s R2=0.70, p<0.0001) for all TMA cores, demonstrating that C1q 
binding is closely associated with C3b deposition in progressive MS (table 4a). C1q signal also correlated 
with C1INH (R2=0.48, p<0.0001) and clusterin (R2=0.58, p<0.0001) signals, providing evidence of a link 
between C activation and regulation in the tissues (table 4a). Separate analysis in GM and WM cores 
showed a positive correlation between all components and regulators in WM (all p<0.05, table 4b); 
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however, in GM many components and regulators showed no correlation, suggesting C dysregulation 
within cortical GM (table 4c).  
 
Classification tree analysis identifies C1q+ cell number as a predictor of the lesion state 
To investigate whether individual or sets of C components strongly predict WML or GML, classification 
tree analysis was performed using the rpart library in R (https://cran.r-
project.org/web/packages/rpart/index.html); this tool partitions data to determine tissue classification. 
Here all cell types were analysed; neurons and glia. For GM cores, C1q staining stood out as a lesion 
discriminator; the cutoff for C1q determined by the model was 8.5: If total C1q positive cells was 
>8.5/core this signified a lesion, and <8.5 signified normal GM.  Likewise, the cutoff determined by the 
model for WM was 13.5. 69% (18/26) of GML tissue cores had >8.5 C1q-positive cells compared to 10% 
(3/30) of NAGM cores and 88% (54/61) of WML tissue cores had >13.5 C1q-positive cells compared to 
2.3% (1/43) of NAWM cores. Although some other C proteins were also predictive, adding in other 
variables did not improve the capacity of the model to successfully classify cores as either lesion or non-
lesion, demonstrating that number of C1q+ cells best discriminates cortical GM and WM MS lesion from 
normal tissue.  
 
Discussion  
TMA methodology is ideally suited for analysing tissue marker expression, revealing interactions 
between large numbers of functionally related proteins and identifying proteins or protein sets that 
correlate with tissue pathology. Our systematic quantitative analysis revealed that increased 
immunostaining for C proteins is a ubiquitous feature of WM and GM lesions in progressive MS. 
Furthermore, the findings suggest that C is dysregulated in GM lesions, leaving cortical GM neurons at 
risk of C-mediated damage due to the presence of C1q, in the absence of key complement regulatory 
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proteins. Indeed, statistical analysis has identified total (neurons and glia) C1q-positive cell number as an 
independent predictor of lesion presence in GM and WM, suggesting its use as a potential biomarker. 
 
Complement activation immunolabels cells in progressive MS lesions. 
Anti-C1q and C3b (iC3b/C3b) positively stained microglia/macrophages (HLA-DR+) of WML and 
neurons and microglia (HLA-DR+) of GML (table 1 and figure 2). The number of anti-C3b and -C1q 
immunolabelled cells were strongly correlated (Pearson coefficient R2=0.70 p<0.0001), providing further 
evidence for C activation via the classical pathway on glia and neurons in MS plaques5,16,21.  We have 
previously demonstrated using double immunolabelling that C1q and iC3b/C3b co-localized on reactive 
astrocytes, microglia and neurons in MS16, and in situ hybridization by ourselves and others showed 
expression of both C3 and C1qA mRNA in neurons and microglia in MS and other neurodegenerative 
diseases23,28,32,37. C activation is a potential stimulus for microglial activation and expression of reactive 
oxygen species and pro-inflammatory cytokines, which are associated with neuronal damage and 
demyelination1,6. Given the paucity of T and B cell lymphocytes in progressive MS lesions 2,26, C 
activation likely represents an important contributor to MS pathology. 
Although the above data support local C activation in lesions, immunolabelling cannot readily 
discriminate whether staining represents protein deposited on the cell surface as a result of activation or 
within the cell cytoplasm as a consequence of biosynthesis. We performed ISH to show C1QA and C3 
mRNA is expressed in cortical neurons co-labelled with the neuron specific marker HuC/D (figure 3). 
C1QA and C3 mRNA have been consistently demonstrated in MS sections23,37 and in glia from 
Huntington’s Disease brain tissue32. Furthermore anti-fibrinogen staining of neurons in MS brain was 
negative supporting the argument that systemic C does not diffuse across the blood-brain barrier in this 
disease. These data are consistent with the interpretation that the blood-brain barrier is grossly intact in 
MS9,16, and that neuronal and glial C staining in MS represents local C biosynthesis28. 
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Complement Regulation in progressive MS 
The increased number of C1q immunolabelled cells in WML is associated with increased C1INH staining 
on the same cells, supporting on-going activation and regulation of the classical pathway in WML. 
Several other C regulators were also increased in WML compared to NAWM; FH, the main regulator of 
the alternative pathway38, CR1, a membrane bound activation pathway regulator, and clusterin, a terminal 
pathway regulator.  There was positive correlation between immunolabelling for C3b and its two main 
regulators, FH and CR1. Staining for FH is complicated by the fact that a battery of homologous FH-
related proteins (FHRs) exist to control FH activity; many FH antibodies cross-react with FHRs. To 
resolve this complexity, we used a panel of anti-FH and anti-FHR antibodies; a polyclonal antibody that 
detects FH and FHRs, two anti-FH mAbs, one of which (MBI-15) is FH-specific, and a mAb that is 
specific for FHRs 1, 2 and 5 (MBC-125). Staining with these antibodies demonstrated that both FH and 
FHRs were present in MS WM lesions, a finding that is in accord with the observed co-localization of FH 
and FHR on kidney and retinal cells13. FHRs are antagonists of FH, blocking its ability to bind C3b and 
regulate the alternative pathway10,11,13,15,31. The demonstration that both FH and FHRs are present in WM 
lesions raises the possibility that C regulation by FH is antagonised by FHRs in the lesions. In contrast to 
the findings in WM, expression of C regulators in GM lesions was minimal, suggesting that C activation 
is poorly controlled in GM.   
 
Complement activation and dysregulation on neurons contribute to neurodegeneration in cortical grey 
matter lesions 
Neuronal cytoplasm C expression has been described in cultured human cells33 in animal models5,28 and 
in human post mortem brain16,23,37. The ISH images shown here demonstrate C1QA and C3 mRNA 
expression in neuronal cytoplasm and nuclei, supporting previously published studies23,37. Here we 
15 
 
showed that significantly increased numbers of C1q immunolabelled neurons (representing >10% of the 
total neurons) were present in GML tissue cores. This finding agrees with the increased C1q 
immunolabelling and C1q mRNA expression described in association with degenerating synapses in MS 
lesions in hippocampus22,37. There was also increased C3b staining in GM lesions which, together with 
the reduced numbers of neurons immunolabelling with C regulators in GML compared to GM, provide 
strong supporting evidence for C dysregulation and activation on neurons in GML.   
 
TMA analysis; an appropriate methodology for analysis of a complex innate immune pathway  
TMA methodology has several advantages over traditional IHC methods; it requires only small amounts 
of formalin fixed tissue and much reduced quantities of reagents, including expensive antibodies, 
compared with traditional IHC31. Furthermore, the TMA approach samples a consistent area of lesion, 
reduces variability of experimental conditions and increases reliability of immunostaining data, making it 
an ideal technique to validate newly generated antibodies36; and compare sets of antibodies as used in this 
study10,11,31. One possible criticism of this approach when applied to MS tissue is the debate regarding 
heterogeneity of MS plaque immunopathology3,21 such that individual cores will show variations in 
pathology. To ensure tissue pathology is uniform between TMA cores we only selected chronic active 
plaques and ensured that the severity of inflammation and pathology was uniform within lesion type by 
controlling for severity of myelin loss, microglial number and activation status (anti-Iba and anti-HLA-
DR) and T and B cell immunostaining. 
 
Conclusion  
The C pathways are pivotal for the CNS innate immune response24; previous studies have shown an 
association between individual C proteins and MS pathology 5,16,21,37; here, using TMA methodology in 
MS tissue in conjunction with control tissues and statistical analyses, we have demonstrated a role for C 
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in progressive MS in both WM and GM lesions and demonstrated an association between functionally 
related C proteins and tissue pathology. Statistical modelling revealed that the number of C1q-positive 
cells in WM or GM was highly predictive of a lesion. In GM lesions, the data suggest that C activation is 
associated with dysregulation; a finding present in other neuroinflammatory diseases such as retinal 
inflammation in Age Related Macular Degeneration (AMD)20,34. AMD is associated with a Tyr402 His 
amino acid substitution in FH and dysregulation and uncontrolled activation of C in the retina. The retinal 
pathology typically includes deposits of C3, C3d, iC3b, terminal pathway components, clusterin and 
FHRs38. In our study, evidence for C dysregulation in GML is provided by an increase of C1q-positive 
neurons with reduced immuno-labelling for the regulators FH, FHR 1/2/5 and C1INH compared to 
NAGM. 
With regard to clinical relevance, measurement of C proteins in serum and CSF is now validated as a 
biomarker of tissue inflammation in MS15. Here we show that tissue-associated C proteins also mark 
disease in progressive MS and may guide future therapeutic approaches targeting the classical pathway.  
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Table 1a. Chronic Progressive MS Case Details. Mean age: 51.1 years, 10F:3M, Mean DTP: 18.2 hours, Mean DD: 25.3 years (n=13 
cases; 2 blocks taken from case MS230). All blocks contained cortical GM and subcortical WM. Abbreviations: DTP; death to 
preservation time, DD; disease duration, SP; secondary progressive, PP; primary progressive. 
Autopsy 
Number 
Age Sex DTP Time 
(hrs) 
MS Disease 
Classification 
Disease 
Duration 
(yrs) 
Cause of Death 
MS106 39 F 18 PP 21 Bronchopneumonia 
MS107 38 M 19 PP >16 Aspiration pneumonia, pulmonary oedema 
MS160 44 F 18 SP 15 Aspiration pneumonia, MS 
MS197 51 F 10 SP 27 Bronchopneumonia, MS 
MS203 53 F 17 SP 27 MS 
MS225 79 F 23 SP 32 MS, diabetes mellitus, recurrent DVT 
MS230 42 F 31 SP 20 MS 
MS234 39 F 15 PP 15 Pulmonary embolism, pneumonia 
MS249 59 F 8 SP  42 Chest infection, heart failure 
MS255 45 M 24 SP 25 Bronchopneumonia, advanced MS 
MS272 64 F 8 SP 37 Aspiration pneumonia Angiomatous 
meningioma (Grade I, WHO 2007) 
MS273 61 M 24 PP 31 UTI, septicaemia, MS 
MS377 50 F 22 SP 21 Aspiration pneumonia 
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Table 1b. Control Cases. Clinical details of neuroinflammatory control cases; n=6, mean age at death = 73.8 years, DTP = 50.3 hours, and 
non-inflammatory control cases; n=3, mean age at death = 75.0 years, DTP = 25.3 hours. Abbreviations: DTP; death to tissue preservation 
time.  
 
Autopsy 
Number 
Age  Sex 
Death to Tissue 
Preservation Time 
(hrs) 
Clinical Diagnosis Neuropathological Findings 
B5125-9 54 M 96 
Encephalitis 
 
Herpes Simplex Encephalitis 
B5046-15 42 M 72 Encephalitis Herpes Simplex Encephalitis 
A173/05 81 F 17 Dementia Alzheimer’s Disease Braak V 
A192/06 96 F 19 
Dementia 
 
Alzheimer’s Disease Braak V 
A303/09 80 M 60 Dementia Alzheimer’s Disease Braak III 
A307/07 90 M 38 Dementia Alzheimer’s Disease Braak VI 
CO38 85 M 27 Ischaemic heart disease None 
CO40 86 F 29 Acute cortical infarction Localized cortical infarction 
CO41 54 M 20 Lung cancer None 
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Antibody Name Antigen/Target 
Type, 
Species 
Isotype Source 
Working 
conc 
(ug/ml) 
Antigen 
Retrieval 
Method 
HLA-DR Microglia mAb, mouse IgG1 DAKO #M0775 39.50 CA/Heat 
Iba-1 Microglia pAb, rabbit IgG 
WAKO/Alpha Labs 
#019-19741 
0.1 SC/Heat 
GFAP Astrocytes mAb, mouse IgG1 DAKO #M0761 7.88 CA/Heat 
MOG Y10 
Myelin oligodendrocyte 
glycoprotein 
mAb, mouse IgG1 In-house 10 CA/Heat 
Fibrinogen Fibrinogen pAb, rabbit IgG Abcam #Ab34269 
1:75 diln of 
stock 
solution 
CA/Heat 
C1q C1q pAb, rabbit IgG 
Alere  
#YYAO13602 
36 CA/Heat 
C3-30 C3b, iC3b mAb, mouse IgG1 In-house 3.21 CA/Heat 
C1INH C1 inhibitor pAb, rabbit IgG In-house 42.3 CA/Heat 
CR1 CR1 pAb, rabbit IgG In-house 6 CA/Heat 
Affinity purified 
anti-Clusterin 
Clusterin pAb, rabbit IgG In-house 2.2 CA/Heat 
Affinity purified 
Poly FH 
FH pAb, rabbit IgG In-house 2.8 CA/Heat 
MBI-15 FH 10-15 SRCs mAb, mouse IgG1 In-house 14 CA/Heat 
Ox-24 N-terminal of FH mAb, mouse IgG1 In-house 56 CA/Heat 
MBC-125 
FH-related proteins 
1/2/5 
mAb, mouse IgG1 In-house 57.2 CA/Heat 
C5aR 
C5a Receptor / Anti-
CD88 
pAb, rabbit IgG 
BD Bioscience 
#550733 
0.31 SC/Heat 
 
Table 2. Antibodies used for Immunohistochemistry. Citraconic anhydride (CA) buffer (pH 7.4) was used for antigen retrieval for all 
antibodies except Iba-1 and C5aR, which used 0.01M Sodium Citrate (SC) buffer (pH 6), biotin-tyramine and ABC staining method.  
Abbreviations: mAb: monoclonal antibody, pAb: polyclonal antibody, Conc: concentration  
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Table 3a. 
Target Non- neuronal cell counts 
NAGM GML Mann-
Whitney U 
test 
Median IQR Median IQR P value 
C1q 0.0 0.00 – 1.00 9.0 4.00 - 19.50 <0.0001 
C3b 1.0 0.00 – 6.00 10.0 2.75 – 24.75 0.00015 
C1INH 12.5 10.00 – 17.00 14.0 4.00 – 20.00 0.82 
CR1 9.0 6.00 – 15.00 17.0 10.00 – 28.00 0.0007 
FH 10.0 5.00 – 13.00 17.5 9.00 – 51.00 0.004 
Clusterin 11.5 8.00 – 18.00 19.0 11.25 – 40.00 0.002 
Ox-24 10.0 6.00 – 11.00 15.5 10.00 – 23.00 <0.0001 
MBI-15 10.0 1.50 – 22.00 21.5 8.75 – 38.25 0.007 
MBC-125 6.0 4.75 – 23.25 34.0 15.00 – 48.00 0.001 
 
 
 
Table 3b. 
Target Neuronal cell counts 
NAGM GML Mann-
Whitney U 
test 
Median IQR Median IQR P value 
C1q 0.0 0.00 – 2.00 4.0 0.00 – 6.00 0.0003 
C3b 1.0 0.00 – 9.00 3.5 2.00 – 8.75 0.18 
C1INH 24.0 18.00 – 28.00 16.0 12.00 – 20.00 0.0003 
CR1 39.0 28.00 – 45.00 25.0 18.50 – 35.00 0.002 
FH 27.0 19.00 – 35.00 26.0 11.70 – 30.00 0.37 
Clusterin 44.5 33.75 – 63.00 42.5 33.30 – 53.50 0.51 
Ox-24 32.5 28.50 – 36.00 21.0 19.00 – 24.75 <0.0001 
MBI-15 24.0 13.00 – 30.00 20.0 10.00 – 28.75 0.21 
MBC-125 41.5 27.80 – 51.00 29.0 17.00 – 34.00 0.005 
 
Mann-Whitney U test was used to compare complement proteins and regulator expression on both non-neuronal (glial) cells and on 
neuronal cells of NAGM and GML. Positive cells were counted per tissue array core (0.28mm2 area) and defined as either non-
neuronal (table 3a) or neuronal (table 3b). Median, IQR and p values are shown. Significance taken at p<0.05 and shown in BOLD. 
Abbreviations: NAGM; normal appearing grey matter, GML; grey matter lesion, IQR; interquartile range. 
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Table 4a.  Total cell counts (all cores) 
Component / 
Regulator 
C1q C3b C1INH Clusterin CR1 FH 
C1q 
 
n/a - - - - - 
C3b R2 = 0.70 
P<0.0001 
n/a - - - - 
C1INH R2 = 0.48 
P<0.0001 
R2 = 0.39 
P<0.0001 
n/a - - - 
Clusterin R2 = 0.58 
P<0.0001 
R2 = 0.50 
P<0.0001 
R2 = 0.47 
P<0.0001 
n/a - - 
CR1 R2 = 0.097 
P = 0.24 
R2 = -0.13 
P = 0.099 
R2 = 0.31 
P<0.0001 
R2 = 0.34 
P<0.0001 
n/a - 
FH R2 = 0.38 
P<0.0001 
R2 = 0.13 
P = 0.12 
R2 = 0.27 
P=0.0004 
R2 = 0.59 
P<0.0001 
R2 = 0.57 
P<0.0001 
n/a 
 
Table 4b.  White Matter cell counts (NAWM, WML; lesion edge and centre) 
Component / 
Regulator 
C1q C3b C1INH Clusterin CR1 FH 
C1q 
 
n/a - - - - - 
C3b R2 = 0.65 
P<0.0001 
n/a - - - - 
C1INH R2 = 0.63 
P<0.0001 
R2 = 0.59 
P<0.0001 
n/a - - - 
Clusterin R2 = 0.63 
P<0.0001 
R2 = 0.61 
P<0.0001 
R2 = 0.58 
P<0.0001 
n/a - - 
CR1 R2 = 0.46 
P<0.0001 
R2 = 0.27 
P = 0.01 
R2 = 0.38 
P<0.0001 
R2 = 0.57 
P<0.0001 
n/a - 
FH R2 = 0.47 
P<0.0001 
R2 = 0.30 
P = 0.007 
R2 = 0.30 
P<0.0001 
R2 = 0.64 
P<0.0001 
R2 = 0.65 
P<0.0001 
n/a 
 
Table 4c. Grey Matter cell counts (NAGM, GML; lesion edge and centre) 
Component / 
Regulator 
C1q C3b C1INH Clusterin CR1 FH 
C1q 
 
n/a - - - - - 
C3b R2 = 0.70 
P<0.0001 
n/a - - - - 
C1INH R2 = 0.37 
P = 0.0065 
R2 = 0.41 
P = 0.0009 
n/a - - - 
Clusterin R2 = 0.25 
P=0.08 
R2 = 0.38 
P = 0.003 
R2 = 0.15 
P = 0.20 
n/a - - 
CR1 R2 = -0.14 
P = 0.31 
R2 = 0.04 
P = 0.77 
R2 = -0.06 
P = 0.62 
R2 = 0.29 
P = 0.009 
n/a - 
FH R2 = 0.17 
P = 0.25 
R2 = 0.33 
P = 0.01 
R2 = 0.07 
P = 0.60 
R2 = 0.39 
P<0.0007 
R2 = 0.53 
P<0.0001 
n/a 
 
Pearson Correlation was used to examine the relationships between cells staining positively for each antibody of the 
Complement Pathways for all tissues types. Correlations were calculated between total cell counts (Table 4a), white matter cell 
counts (Table 4b) and grey matter cell counts (Table 4c). 
 
Significant correlation was p<0.05 and shown in BOLD. Abbreviations: n/a = not applicable, R2 = regression coefficient. 
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Figure Legends 
 
Figure 1. Tissue Characterization and TMA Methodology. Panel A; Luxol Fast Blue (LFB) staining and 
antibodies to MOG and HLA were used to characterize whole sections from FFPE MS tissue blocks in terms of 
demyelination and inflammation. All sampled white matter lesions were classified as chronic active inflammatory 
lesions and cortical grey matter lesions classified based on their location within the neocortex. Three cores per 
region of interest, each of 0.6mm diameter (0.28mm2 area) were extracted using a MicroArrayer from the donor 
block and transferred to a recipient in a predetermined grid location. Panel B; examples of whole TMAs stained with 
LFB, MOG and HLA and cores from each area of interest; normal appearing white matter (NAWM), white matter 
lesion edge and lesion centre, normal appearing grey matter (NAGM), grey matter lesion edge and lesion centre. 
Cores from lesion edge and lesion centre were combined and labelled white matter lesion (WML) and grey matter 
lesion (GML) for analysis. Scale bars are shown. Abbreviations: LFB; Luxol fast blue, MOG; myelin 
oligodendrocyte glycoprotein, FFPE; formalin fixed paraffin embedded.  
 
 
 
Figure 2. Microglial activation and complement anaphylatoxin receptor expression in MS lesions  
Panel A shows a stacked bar chart illustrating the constituent cell types in each of our ROIs. Cells morphologically 
resembling microglia, astrocytes and neurons were quantified. There was a significant increase in the numbers of 
GFAP positive astrocytes and HLA positive microglia/ macrophages in WML compared to NAWM, and in GML 
compared to NAGM (*p<0.05). Overall there was no significant difference in the total number of Iba-1 positive 
microglia in any tissue type or of grey matter neurons whether in lesion or non-lesion. 
Panel B; C5aR immunostaining identified cells with microglial/macrophage morphology. There was a significant 
increase in C5aR stained cells in WML as compared to NAWM (p=0.00295). IHC shows C5aR-positive staining in 
NAWM, WML, GML and NAGM (clockwise from top left) of TMA cases MS272 and MS273.  
 
Median, IQR and full range of data shown. Scale bars are shown. 
 
Abbreviations: NAGM; normal appearing grey matter, GML; grey matter lesion, WM; white matter, WML; white 
matter lesion, C5aR; C5a receptor.  
 
 
Figure 3. Complement Component Expression in MS tissue. 
We quantified the number of (A) C1q and (B) C3b immunostained cells of all types in normal and lesion cores.  
Panel A; box plots revealed a significant increase in C1q positive cells in WML tissue and in GML tissue compared 
to normal appearing WM and GM, respectively. C1q IHC shows immuno-positive cells with astrocytic morphology 
in WML of case MS225, neuronal morphology in GML from case MS272 and an absence of staining in NAWM 
(case MS203) and NAGM (case MS230).  Inset: In situ hybridisation shows neurons (arrow; brown DAB reaction 
product) positive for complement C1QA mRNA (a), whilst the scrambled probe (ISH) is negative (b). All neurons 
are identified by expression of HuC/D protein by immunohistochemistry (blue reaction product). 
Panel B; Quantification of C3b positive cells. There was a significant increase in the number of C3b positive cells in 
WML tissue and in GML tissue compared to normal appearing WM and GM, respectively. IHC shows glial C3b 
staining from WML of case MS225 (arrows mark positive glia), neuronal and glial staining from GML and GM of 
case MS272 (inset shows magnified neuron indicating cytoplasmic and surface staining patterns). A decrease in 
cellular staining is shown in WM from case MS230. Inset: In situ hybridisation shows neurons (arrow, brown DAB 
reaction product) express the mRNA transcript for complement C3 (a) whilst the ISH sense probe for C3 is negative 
(b). All neurons are identified by expression of HuC/D protein by immunohistochemistry (blue reaction product). 
 
Median, IQR and full range of data shown. Abbreviations: NAGM; normal appearing grey matter, NAWM; normal 
appearing white matter, WM; white matter, GM; grey matter. 
 
 
Figure 4. Complement Regulator Expression in MS white matter. 
Each of panels A-G: Box plots show total immunostained cell counts and examples of typical staining in WML (top) 
and NAWM (bottom) of C pathway regulators; C1INH, CR1, FH (as stained with polyclonal anti-FH antibody, and 
mAb Ox-24 and MBI-15), the terminal complex regulator, clusterin and FH-Related protein (FHR). All regulators 
are shown to be increased in WML compared to NAWM (all p<0.05). 
Panel A: WML and NAWM IHC from case MS230, inset shows C1INH astrocytic staining from case MS203. Panel 
B: CR1 positive glia in WML of case MS273 and reduced staining in NAWM of case MS230. Panel C: Positive FH 
glial staining in an active NAWM peri-plaque region of case MS197 and lack of cellular staining in NAWM of case 
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MS106. Panel D: Terminal pathway regulator, clusterin positive glia of case MS197 WML edge and reduced in 
NAWM of case MS230. Monoclonal antibodies Ox-24 and MBI-15 both recognize epitopes on FH (N-terminal and 
mid-section, respectively), MBC-125 is specific for FHR proteins 1/2/5. Panel E: Ox-24 positive glia from WML 
and NAWM of case MS377. Panel F: ramified MBI-15 glia of WML centre from case MS377 and reduced staining 
in NAWM of case MS273. Panel G: FHR positive active glia from WML edge of case MS197 and lack of cellular 
staining in NAWM of the same case. 
Median, IQR and full range of data shown. Abbreviations: NAGM; normal appearing grey matter, NAWM; normal 
appearing white matter, C1INH; C1 inhibitor, CR1; complement receptor 1, FH; Factor H; FHR; Factor H related 
proteins. 
 
 
 
Figure 5. Complement Regulator Expression in MS grey matter.  
Each of panels A-G: Box plots show total immunostained cell counts and examples of typical staining in GML (top) 
and NAGM (bottom) of C pathway regulators; C1INH, CR1, FH (as stained with polyclonal anti-FH antibody, and 
mAb Ox-24 and MBI-15), the terminal complex regulator, clusterin and FH-Related protein (FHR). In contrast to 
white matter, our analysis revealed the total number of complement regulator positive cells to be unchanged 
between normal and lesioned GM with the exception of clusterin.  
Panel A; C1INH positive neurons and glia in GML and NAGM of case MS249. Panel B: CR1 positive GML cells of 
case MS273 and NAGM of case MS377. Panel C: Polyclonal anti-FH staining of neuritic-like processes (black 
arrow) and granular areas within neurons (blue arrows) in NAGM of case MS160 and GML of case MS225. Panel 
D: neuronal clusterin staining in GML of case MS272 and NAWM of case MS249. Panel E: Ox-24 (anti-FH) 
positively stained neurons (blue arrow) and glia (black arrow) from GML and NAGM of case MS255. Panel F: 
MBI-15 (anti-FH specific) positively stained GML and NAGM neurons (blue arrows) of cases MS377 and MS234, 
respectively. Panel G: FHR positive staining in GML and NAGM of case MS225. 
 
Median, IQR and full range of data shown. Abbreviations: NAGM; normal appearing grey matter, NAWM; normal 
appearing white matter, C1INH; C1 inhibitor, CR1; complement receptor 1, FH; Factor H; FHR; Factor H related 
proteins. 
 
 
 
 
Supplementary Figure 1. Control Immunohistochemistry examples; non-inflammatory control tissue and 
anti-fibrinogen and IgG1 isotype controls.  Panel A: Tissue sections from non-inflammatory control cases (CO38, 
CO40, CO41) showing examples of complement staining in NAWM and NAGM. Panel B: lack of cellular 
fibrinogen staining in NAWM of TMA case MS255. Panel C: fibrinogen positive blood vessel wall surrounded by 
immuno-negative neurons of NAGM of TMA case MS234. Panels D & E: fibrinogen staining in human kidney as a 
positive control. Panel F: IgG control staining. Panel G: no primary antibody negative control. 
 
 
 
Supplementary Figure 2. Control Immunohistochemistry examples. Tissue sections from Herpes simplex 
encephalitis (HSV [cases B5125-9 and B5046-15]) immunostained for C proteins investigated in this study; (A) 
polyclonal antibody to C1q immunolabels several neurons within GM; (B) C3b+ glia (arrows) within the WM of 
temporal lobe; (C) C3b+ degenerating neurons within the temporal cortex; (D) C1INH+ neurons; (E) clusterin+ 
immunolabelled axons (arrow) and glia within WM of temporal lobe; (F) clusterin+ neurons and occasional glia 
within GM; (G) C5aR+ cells with a microglia/ macrophage morphology in a perivascular distribution; (H) Ramified 
C5aR+ glia in WML edge.  All images x40 magnification. 
 
 
Supplementary Figure 3. Control Immunohistochemistry examples. Sections from paraffin wax embedded 
formalin fixed Alzheimer’s disease cerebral cortex immunostained for C proteins; (A) C1q antibody showing 
positive immunolabelling of pyramidal neurons (A303/09); (B) C3b immunolabelling neurons and amyloid plaques, 
and occasional glia (A307/07); (C) C1INH labelled glia (A173/05); (D) polyclonal anti-FH staining with 
characteristic granular immunolabelling within the neuronal cytoplasm (A173/05); (E) MBC-125 (FHR protein) 
immunolabelling of neuronal cytoplasm (A192/07); (F) Ox-24 antibody demonstrating a similar pattern of 
immunolabelling of neurons as seen with the polyclonal anti-FH anti-sera (A307/07); (G) MBI-15 (FH-specific) 
antibody immunolabelling of  neuronal cytoplasm (A307/05); (H) Anti-clusterin stained neurons from case A303; 
(I)  CR1 positive neurons from GM of case A307.  
28 
 
 
 
 
 
 
 
 
 
